79925-16-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-CYANOPHENOXY)-2-METHYLPROPANOIC ACID is used as an intermediate in the synthesis of various pharmaceuticals for its ability to inhibit the growth of certain bacteria and fungi, contributing to the development of new treatments and medications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(4-CYANOPHENOXY)-2-METHYLPROPANOIC ACID is utilized as an intermediate in the production of compounds that help control and prevent the growth of harmful bacteria and fungi in agricultural settings, thereby enhancing crop protection and yield.
Used in Organic Synthesis:
2-(4-CYANOPHENOXY)-2-METHYLPROPANOIC ACID serves as a building block in the preparation of other chemical compounds due to its structural versatility, allowing for the creation of a wide range of organic molecules for various applications across different industries.

InChI:InChI=1/C11H11NO3/c1-11(2,10(13)14)15-9-5-3-8(7-12)4-6-9/h3-6H,1-2H3,(H,13,14)

Upstream product

• 67-66-3 chloroform 
• 767-00-0 4-cyanophenol 
• 67-64-1 acetone 
• 18672-07-6 2-(4-cyanophenoxy)-2-methylpropionic acid ethyl ester 

Downstream Products

• 121809-90-3 4-(4-ethylcarbamatophenylureido)phenoxyisobutyric acid 
• 121809-84-5 4-(2-chloro-5-nitrophenylureido)phenoxyisobutyric acid 
• 121809-85-6 4-(4-chloro-3-nitrophenylureido)phenoxyisobutyric acid 
• 121809-81-2 2-Methyl-2-{4-[3-(2,4,5-trichloro-phenyl)-ureido]-phenoxy}-propionic acid 
• 121809-88-9 2-{4-[3-(4-Acetoxy-phenyl)-ureido]-phenoxy}-2-methyl-propionic acid 
• 121809-63-0 2-{4-[2-(4-Chloro-benzoylamino)-acetylamino]-phenoxy}-2-methyl-propionic acid 
• 121809-83-4 2-Methyl-2-{4-[3-(3-nitro-phenyl)-ureido]-phenoxy}-propionic acid 
• 121809-69-6 4-(3,4-dimethoxyphenylureido)phenoxyisobutyric acid 
• 121809-71-0 2-[4-(3-Benzo[1,3]dioxol-5-yl-ureido)-phenoxy]-2-methyl-propionic acid 
• 121809-78-7 2-{4-[3-(2,4-Dichloro-phenyl)-ureido]-phenoxy}-2-methyl-propionic acid 
• 121809-79-8 2-{4-[3-(2,5-Dichloro-phenyl)-ureido]-phenoxy}-2-methyl-propionic acid 
• 121809-77-6 4-(2,3-dichlorophenylureido)phenoxyisobutyric acid 
• 121809-94-7 4-(4-carboxyphenylureido)phenoxyisobutyric acid 
• 121809-67-4 4-(2,4,6-trimethylphenylureido)phenoxyisobutyric acid 

Relevant academic research and scientific papers

Design, synthesis of novel, potent, selective, orally bioavailable adenosine A2A receptor antagonists and their biological evaluation

Our initial structure-activity relationship studies on 7-methoxy-4-morpholino-benzothiazole derivatives featured by aryloxy-2-methylpropanamide moieties at the 2-position led to identification of compound 25 as a potent and selective A2A adenosine receptor (A2AAdoR) antagonist with reasonable ADME and pharmacokinetic properties. However, poor intrinsic solubility and low to moderate oral bioavailability made this series unsuitable for further development. Further optimization using structure-based drug design approach resulted in discovery of potent and selective adenosine A2A receptor antagonists bearing substituted 1-methylcyclohexyl-carboxamide groups at position 2 of the benzothiazole scaffold and endowed with better solubility and oral bioavailability. Compounds 41 and 49 demonstrated a number of positive attributes with respect to in vitro ADME properties. Both compounds displayed good pharmacokinetic properties with 63% and 61% oral bioavailability, respectively, in rat. Further, compound 49 displayed oral efficacy in 6-OHDA lesioned rat model of Parkinson diseases.

Amido compounds and their use as pharmaceuticals

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

Allosteric Modifiers of Hemoglobin. 1. Design, Synthesis, Testing, and Structure-Allosteric Activity Relationship of Novel Hemoglobin Oxygen Affinity Decreasing Agents

Three isomeric series of 2-(aryloxy)-2-methylpropionic acids were prepared and studied for their ability to decrease the oxygen affinity of human hemoglobin A.The isomeric aryloxy groups included 4-methyl>phenoxy, 4-(arylacetamido)phenoxy, and 4-methyl>phenoxy.A total of 20 compounds were synthesized and tested.Structure-activity relationships are presented.Several of the new compounds were found to be strong allosteric effectors of hemoglobin.The two most active compounds are 2-methyl>phenoxy>-2-methylpropionic acid and the corresponding 3,5-dimethyl derivative.The latter two compounds have been compared to other known potent allosteric effectors in the same assay and show greater activity.Both compounds also exhibit a right shift in the oxygen equilibrium curve when incubated with whole blood.The new compounds may be of interest in clinical or biological areas that require or would benefit from a reversal of depleted oxygen supply (i.e., ischemia, stroke, tumor radiotherapy, blood storage, blood substitutes, etc.).They are also structurally related to several marketed antilipidemic agents.

Method of synthesis and novel compounds for pharmaceutical uses

The present invention is concerned with a process for the synthesis of substituted arylureidophenexymethyl propionic acids and an analogous benzamides series of compounds which have activity in the dissociation of oxygen from hemoglobin. In addition, the

Synthesis and Investigation of Effects of 2-amino>phenoxy>-2-methylpropionic Acids on the Affinity of Hemoglobin for Oxygen: Structure-Activity Relationships

A series of 2-carbonyl>amino>phenoxy>-2-methylpropionic acids and other substituted phenoxyacetic acids were synthesized and tested for their ability to reduce the affinity of hemoglobin for oxygen. 2-4-(3,4,5-Trichloro